Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Recurrence 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Hodgkin Disease 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 46fludarabine phosphate 24Busulfan 22Peripheral Blood Stem Cell Transplantation 20Radiotherapy 19Filgrastim 19Mycophenolic Acid 18Antilymphocyte Serum 18Cyclosporine 17Whole-Body Irradiation 16Rituximab 16Etoposide 16Methotrexate 15Melphalan 15Methylprednisolone 14Tacrolimus 12Cytarabine 12Vincristine 10Prednisone 10Doxorubicin 10Cord Blood Stem Cell Transplantation 10Thiotepa 6Granulocyte Colony-Stimulating Factor 6Leucovorin 5sargramostim 4fludarabine 4Daunorubicin 4glofitamab 3Sirolimus 3Methylprednisolone Hemisuccinate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Dendritic Cell Sarcoma, Interdigitating × iratumumab × Clear all
NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Bristol-Myers Squibb

Phase 2 Withdrawn
45 enrolled
DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡